New Pharmaceuticals research report from GBI Research is now available from Fast Market Research
Boston, MA -- (SBWIRE) -- 08/08/2012 -- GBI Research, the leading business intelligence provider, has released its latest research, "Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise", which provides an overview of the discovery and development of therapeutic drug combinations and multi-target drugs for oncology. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an insight into different methods and techniques used to identify and design drugs that act upon multiple targets in the treatment of cancer. It also focuses on the design and development of combination therapies to address multiple targets in oncology and the challenges surrounding this.
View Full Report Details and Table of Contents
Pipeline analysis of the Phase III oncology pipeline focuses on indications such a lung cancer, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, leukemia, lymphoma, head and neck cancer and multiple myeloma. The most common types of drug combinations used to treat these indications are highlighted and promising molecules in each indication have been identified.
- An introduction to network biology and its implications in the design of drugs and cancer therapy.
- The rationale behind the use of multi-target drugs or combination therapy to address multiple targets in cancer treatments.
- A comparison of the strengths and weaknesses in the multi-target approach to the use of drug combinations.
- Methods and techniques for the discovery and design of multi-target drugs.
- Methods for designing combination therapies for cancer and the challenges involved in the process.
- Late-stage pipeline analysis of combination therapies in oncology in indications such as lung cancer, breast cancer, colorectal cancer, prostate cancer and ovarian cancer.
Reasons to Get this Report
- Develop business strategies by understanding the trends shaping and driving research in the field of multi-target therapies.
- Understand the processes being used to design and develop multi-target drugs and combination therapies and identify some of the challenges involved in this.
- Identify key molecules in development being used in combination based on indication.
- Reinforce R&D pipelines by identifying common drug class combinations in the pipeline for different cancer indications.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline
- Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
- Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
- Millennium Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Cell Therapeutics, Inc. (CTIC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Genentech, Inc. (DNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- OSI Pharmaceuticals, Inc. (OSIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Product Profiles: Non-Small Cell Lung Cancer
- R&D Trends: Non-Small Cell Lung Cancer - Mutation analyses continue driving treatment choices
- Genta Incorporated (GNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile